MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$82,196K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of avai...
Stock-based compensation
Proceeds from issuance of common...
Others
Negative Cash Flow Breakdown
Purchases of available-for-sale ...
Net loss
Accrued compensation
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Net loss
-78,047
-37,804
-36,787
-86,716
Stock-based compensation
6,678
2,702
2,699
4,679
Accretion of discounts on available-for-sale marketable securities
920
1,368
1,567
3,953
Non-cash interest expense
231
72
-
-
Depreciation and amortization expense
785
368
415
1,016
Impairment of capitalized software
0
0
0
648
Gain on sale of property and equipment
47
-20
-40
-
Non-cash lease expense
963
749
732
1,419
Prepaid expense and other current assets
526
-58
1,137
-1,972
Other non-current assets
-1,541
-483
958
505
Accounts payable
-2,373
2,151
-6,801
5,193
Accrued compensation
-4,509
3,030
1,989
88
Other accrued expenses and current liabilities
-4,443
-644
-1,172
1,016
Other non-current liabilities
-
-
0
-
Accrued license expense - related party
-
-2,500
-
-
Operating lease liability
-1,236
-844
-774
-1,721
Net cash used in operating activities
-81,903
-33,527
-43,321
-76,864
Purchases of available-for-sale marketable securities
147,823
115,951
72,821
175,851
Proceeds from maturities of available-for-sale marketable securities
134,300
99,201
95,700
210,800
Internal-use software development costs
255
538
390
200
Proceeds from sale of property and equipment
-
0
70
-
Purchases of property and equipment
293
-1
2
4
Net cash (used in) provided by investing activities
-14,071
-17,287
22,557
34,745
Proceeds from issuance of common stock upon initial public offering and underwritten public offering, net of underwriting commissions
-
98,968
0
0
Proceeds from issuance of common stock under the atm facility, net of agent's fees
2,487
16,940
-
-
Proceeds from borrowing of the term loan, net of issuance costs
-
24,700
-
-
Proceeds from exercise of common stock options
1,896
333
1,651
3
Principal paid on finance lease liabilities
181
85
120
603
Payments for offering costs
138
63
0
412
Taxes paid related to net share settlement upon vesting of restricted stock units
377
50
43
51
Net cash provided by (used in) financing activities
3,687
140,743
1,488
-1,063
Net decrease in cash, cash equivalents and restricted cash
-92,287
89,929
-19,276
-43,182
Cash, cash equivalents and restricted cash, at beginning of period
124,644
34,715
97,173
-
Cash, cash equivalents and restricted cash, at end of period
32,357
-
-
-
Cash and cash equivalents
31,806
-
-
-
Restricted cash
551
-
-
-
Cash, cash equivalents and restricted cash at end of period
32,357
124,644
34,715
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock under the...
$2,487K
Proceeds from exercise of
common stock options
$1,896K
(63100.00%↑ Y/Y)
Net cash provided by
(used in) financing...
$3,687K
(446.85%↑ Y/Y)
Canceled cashflow
$696K
Net decrease in
cash, cash...
-$92,287K
(-113.72%↓ Y/Y)
Canceled cashflow
$3,687K
Stock-based compensation
$6,678K
(42.72%↑ Y/Y)
Other non-current
assets
-$1,541K
(-405.15%↓ Y/Y)
Non-cash lease expense
$963K
(-32.14%↓ Y/Y)
Depreciation and
amortization expense
$785K
(-22.74%↓ Y/Y)
Non-cash interest
expense
$231K
Proceeds from maturities
of...
$134,300K
(-36.29%↓ Y/Y)
Taxes paid related to
net share...
$377K
(639.22%↑ Y/Y)
Principal paid on finance
lease liabilities
$181K
(-69.98%↓ Y/Y)
Payments for offering
costs
$138K
(-66.50%↓ Y/Y)
Net cash used in
operating activities
-$81,903K
(-6.56%↓ Y/Y)
Net cash (used in)
provided by investing...
-$14,071K
(-140.50%↓ Y/Y)
Canceled cashflow
$10,198K
Canceled cashflow
$134,300K
Net loss
-$78,047K
(10.00%↑ Y/Y)
Accrued compensation
-$4,509K
(-5223.86%↓ Y/Y)
Purchases of
available-for-sale marketable...
$147,823K
(-15.94%↓ Y/Y)
Other accrued
expenses and current...
-$4,443K
(-537.30%↓ Y/Y)
Accounts payable
-$2,373K
(-145.70%↓ Y/Y)
Operating lease liability
-$1,236K
(28.18%↑ Y/Y)
Accretion of discounts on
available-for-sale marketable...
$920K
(-76.73%↓ Y/Y)
Prepaid expense and
other current assets
$526K
(126.67%↑ Y/Y)
Gain on sale of
property and equipment
$47K
Purchases of property and
equipment
$293K
(7225.00%↑ Y/Y)
Internal-use software
development costs
$255K
(27.50%↑ Y/Y)
Buy us a coffee
Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc. (KYTX)